Literature DB >> 32815916

A case-report of two patients with hereditary protein S deficiency treated by rivaroxaban.

Jianyao Lou1, Li Yin2, Xueying Ke3, Liang Zhang2, Fangfang Xu4, Zhenjie Liu2.   

Abstract

: Hereditary protein S deficiency is an autosomal dominant disorder associated with a high risk of venous thromboembolism (VTE) and usually results from mutations of PROS1. Historically heparin and warfarin have been applied as recommended treatment of VTE. Recent researches showed that rivaroxaban provided more consistent and predictable anticoagulation than warfarin. However, it is unknown whether rivaroxaban is effective for the treatment of VTE in patients with thrombophilia, including protein S deficiency, due to lack of evidence. Here, we report two cases of recurrent VTE in two patients with hereditary protein S deficiency, owing to the same nonsense mutation in PROS1, which were successfully treated by rivaroxaban monotherapy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32815916     DOI: 10.1097/MBC.0000000000000929

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

1.  Rapid identification of a pathogenic variant of PROS1 in a thrombophilic family by whole exome sequencing: A case report.

Authors:  Wenwen Zhang; Chen Huang; Wei Zhou
Journal:  Medicine (Baltimore)       Date:  2021-12-30       Impact factor: 1.889

Review 2.  Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.

Authors:  Lina Khider; Nicolas Gendron; Laetitia Mauge
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

Review 3.  Protein S: function, regulation, and clinical perspectives.

Authors:  Rinku Majumder; Tina Nguyen
Journal:  Curr Opin Hematol       Date:  2021-09-01       Impact factor: 3.218

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.